Eli Lilly’s oral GLP-1 therapy, orforglipron, met all primary and key secondary endpoints in the Phase III ACHIEVE-2 and ACHIEVE-5 studies, showing significant A1C reduction, weight loss, and ...

Eli Lilly (NYSE:LLY) announced on Wednesday that its oral weight loss candidate, orforglipron, reached the main goals in two ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking ...

Monitoring your A1C is essential for both preventing and managing type 2 diabetes. Why? Regular testing can help detect elevated blood sugar levels and assess the effectiveness of your current ...

An epidemic of Type 2 diabetes continues to plague the United States, leading to calls for reassessing how the disease is ...

During November, the American Red Cross is partnering with National Diabetes Month to offer free hemoglobin A1C testing to ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials.

Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data ...

Hypothyroidism during pregnancy may have a negative metabolic impact in women with gestational diabetes, with high TSH levels ...

Metformin is a safe and effective oral medication for people with type 2 diabetes. Here's how it can help regulate ...

After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.